Serine Protease

Items 1-50 of 149

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. serine protease inhibitor

    Nafamostat is an anticoagulant. Broad spectrum serine protease inhibitor. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma.
  2. Serine protease inhibitor

    BCX 1470 is serine protease inhibitor. BCX 1470 blocks the esterolytic and hemolytic activities of the complement enzymes Cls and factor D in vitro.
  3. Serine protease inhibitor

    BCX 1470 is serine protease inhibitor. BCX 1470 blocks the esterolytic and hemolytic activities of the complement enzymes Cls and factor D in vitro.
  4. Camostat mesylate is an orally active protease inhibitor. Known to inhibit trypsin and various inflammatory proteases including plasmin, kallikrein and thrombin.
  5. Serine/cysteine protease inhibitor

    PMSF is an irreversible serine/cysteine protease inhibitor.
  6. neutrophil elastase inhibitor

    Avelestat, also known as AZD9668, is a novel, oral inhibitor of neutrophil elastase (NE).
  7. Serine protease inhibitor

    AAF-CMK is a serine protease inhibitor which irreversibly inhibits TPPII (tripeptidyl peptidase II), a giant protease which may substitute for some proteasome functions1, and reversibly inhibits Cln2 (TPPI).
  8. Neutrophil elastase inhibitor

    Sivelestat sodium salt is a selective leukocyte elastase inhibitor (IC50 = 44 nM) that displays no activity at a range of other proteases. It inhibits NF-kB activation and LTB4-induced neutrophil transmigration in vitro.
  9. Cysteine Protease inhibitor

    Leupeptin hemisulfate is a reversible inhibitor of trypsin-like and cysteine proteases such as calpain.
  10. Neutrophil elastase inhibitor

    Sivelestat is a cell-permeable sulfanilide compound that acts as a potent, substrate-competitive, and highly specific inhibitor of neutrophil elastase (IC50 = 19-49 nM in rat, rabbit, hamster, human, and mouse leukocyte elastase).
  11. serine protease inhibitor

    Aprotinin is a small protein serine protease inhibitor, used to reduce perioperative blood loss and transfusion.
  12. serine protease inhibitor

    AEBSF HCl is a broad spectrum, irreversible serine protease inhibitor.
  13. HLE inhibitor

    SSR 69071 is a high affinity, potent inhibitor of Neutrophil Elastase (human leukocyte elastase, HLE) (IC50 = 3.9 nM).
  14. serine/threonine phosphatase inhibitor

    Fumonisin B1 is a fungal metabolite produced by Fusarium moniliforme, that has been shown to inhibit protein serine/threonine phosphatases (PP1, PP2A, PP2B, PP2C, and PP5/T/K/H), and is most effective with PP5.
  15. Neutrophil elastase inhibitor

    Sivelestat sodium is a competitive inhibitor of human neutrophil elastase, also inhibits leukocyte elastase obtained from rabbit, rat, hamster and mouse.
  16. serine hydrolase inhibitor

    AA26-9 is a potent and broad-spectrum serine hydrolase inhibitor.
  17. uPA inhibitor

    ZK824859 is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC50s of 79?nM, 1580?nM and 1330?nM for human uPA, tPA, and plasmin, respectively.
  18. PCSK9 inhibitor

    SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1, Figure 1.
  19. uPA system inhibitor

    UKI-1 is a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
  20. anti-secretagogue of PCSK9

    R-IMPP is an anti-secretagogue of PCSK9 (IC50=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation.
  21. serine protease inhibitor

    Nafamostat is an anticoagulant. Broad spectrum serine protease inhibitor. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma.
  22. serine protease inhibitor

    Nafamostat hydrochloride is an anticoagulant. Broad spectrum serine protease inhibitor. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma.
  23. serine protease inhibitor

    Upamostat is a serine protease inhibitor. Upamostat is the orally available prodrug of the WX-UK1, which is a urokinase plasminogen activator (uPA) inhibitor.
  24. PKK inhibitor

    Avoralstat is an oral plasma kallikrein (PKK) inhibitor, used for the treatment of hereditary angioedema.
  25. Anti-ulcer agent

    Cetraxate (DV-1006) Hydrochloride (HCl) is a mucosal protective agent and an anti-ulcer drug candidate. Cetraxate raises levels of calcitonin gene-related peptide and substance P in human plasma.
  26. proteinase inhibitor

    FOY 251, an anti-proteolytic active metabolite Camostate, acts as a proteinase inhibitor. FOY 251 inhibits SARS-CoV-2 infection in cells assay.

  27. serine proteases inhibitor

    Benzamidine hydrochloride is an reversible competitive inhibitor of trypsin-like serine proteases, with Kis of 97 ?M, 21 ?M, 20 ?M and 110 ?M for uPA, trypsin, tryptase and factor Xa, respectively.
  28. Pep2-8 is a PCSK9 inhibitor with a binding KD of 0.7 μM and an IC50 of 1.4 μM.
  29. Irucalantide is kallikrein inhibitor.
  30. Serine Protease

    Proteinase K is a nonspecific serine protease that effectively digests a wide variety of proteins. It exhibits robust activity in the presence of SDS or urea and functions across a broad pH range (4-12), temperature, and ionic conditions. This enzyme is commonly utilized in the extraction and detection of viral nucleic acids, making it a valuable tool in molecular biology and diagnostic applications.
  31. 14-3-3 Protein-Protein Interaction Inhibitor

    (E)-FOBISIN101 is a selective inhibitor of 14-3-3 protein-protein interactions, demonstrating IC50 values of 9.3 μM and 16.4 μM for the disruption of 14-3-3ζ and 14-3-3γ binding to PRAS40, respectively. This compound also inhibits 14-3-3's interactions with Raf-1 and proline-rich AKT substrates, and it neutralizes the activating effect of 14-3-3 on exotoxin S ADP-ribosyltransferase. (E)-FOBISIN101 is valuable for research into 14-3-3-mediated pathways in cancer biology.
  32. Plasminogen Activator

    Alteplase is a recombinant tissue plasminogen activator that acts primarily as a thrombolytic agent by converting plasminogen to plasmin, which leads to fibrinolysis. This compound is crucial in the management of acute ischemic stroke, pulmonary embolism, and acute myocardial infarction. Alteplase is also utilized for the treatment of occluded catheters, facilitating the restoration of vascular patency in clinical settings.
  33. VRK1 Inhibitor

    VRK-IN-1 is a selective inhibitor of vaccinia-related kinase 1 (VRK1), with an IC50 value of 150 nM. This compound modulates the activity of human Ser/Thr protein kinases that are implicated in enhanced cell division and various neurological disorders. Its application in research may provide insights into cellular proliferation and potential therapeutic approaches for neurological conditions.
  34. WNK1 Inhibitor

    WNK1-IN-1 is a selective inhibitor of WNK1, exhibiting an IC50 of 1.6 μM. It effectively inhibits the phosphorylation of OSR1 with an IC50 of 4.3 μM. This compound is relevant for studies focused on blood pressure regulation and various aspects of cancer research, making it a valuable tool for elucidating the role of WNK1 in pathophysiological processes.
  35. KIAA1363/AADACL1 Inhibitor

    JW480 is a selective inhibitor of KIAA1363/AADACL1 that displays potent oral bioactivity, with IC50 values of 12 nM against human KIAA1363 and 20 nM against mouse KIAA1363. Its mechanism involves inhibition of lipid deacetylase activity, which suppresses HAG metabolism and reduces retinyl ester hydrolase function in hepatic stellate cells. JW480 has demonstrated significant effects in reducing MAGE lipid levels and inhibiting critical processes such as migration, invasion, and tumor growth in prostate cancer cells. Additionally, it impacts platelet function and thrombosis, making it a valuable reagent for research in prostate cancer and thrombotic disorders.
  36. Serine Protease

    Recombinant enterokinase (rEK) is a serine protease that functions as the physiological activator of trypsinogen, converting it into its active form, trypsin. This enzyme is essential for various biochemical assays and applications involving protein digestion and processing. Recombinant enterokinase is widely used in research focused on proteolytic processes, enzyme activation, and protein purification techniques.
  37. ASS1 Enzyme ctivators

    LM2I is an argininosuccinate synthase (ASS1) enzyme activator derived from Spinosyn A. This compound demonstrates significant antiproliferative activity against various colorectal cancer cell lines and xenograft tumors. LM2I effectively inhibits colorectal cancer cell growth through the EGFR signaling pathway, making it a valuable tool for research in cancer biology and therapeutic development targeting ASS1.
  38. Protease Inhibitor

    Benzamidine is a competitive protease inhibitor targeting enzymes such as plasmin, trypsin, and thrombin, effectively preventing the hydrolytic cleavage of glucagon. It is primarily employed to stabilize glucagon in human plasma and blood samples during collection, storage, and analysis, thereby ensuring accurate detection outcomes in research applications. While Benzamidine can induce slight single-strand DNA breaks at elevated concentrations, it demonstrates minimal overall genotoxicity. Additionally, it may interfere with certain glucagon antisera, although it does not significantly impact the affinity of key antigen-antibody interactions at specific concentrations.
  39. CITK Inhibitor

    C3TD879 is a potent CITK inhibitor that targets the catalytic activity of CITK with an IC50 of 12 nM. It demonstrates a strong binding affinity for full-length human CITK in cellular assays, with a NanoBRET Kd of less than 10 nM. This compound serves as a valuable chemical probe for exploring the intricate biological functions associated with CITK, making it an essential tool for research in cell signaling and cancer biology.
  40. Trypsin Inhibitor

    SFTI-1 is a cyclic peptide that functions as a potent trypsin inhibitor, comprising 14 amino acid residues. This compound is categorized within the Bowman-Birk class of inhibitors, notable for its remarkable stability and efficacy. SFTI-1 is a valuable tool for investigating peptide drug design and can significantly enhance research related to protease activity modulation.
  41. HTRA1 Inhibitor

    HTRA1-IN-1 is a potent and selective inhibitor of high temperature requirement A serine peptidase 1 (HTRA1) with an IC50 of 13 nM. This compound is instrumental in research related to HTRA1-associated conditions, including age-related macular degeneration (AMD), osteoarthritis, and rheumatoid arthritis. By inhibiting HTRA1, it offers potential insights into therapeutic strategies for these diseases.
  42. PKR Inhibitor

    PKR-IN-C51 is an ATP-competitive inhibitor of the double-stranded RNA-activated protein kinase (PKR), demonstrating an IC50 of 9 μM. This compound effectively inhibits intracellular PKR activation in a dose-dependent manner in primary mouse macrophages. PKR-IN-C51 is valuable for research into PKR-mediated signaling pathways and therapeutic strategies targeting inflammatory responses.
  43. Serine Proteases Inhibitor

    Benzamidine hydrochloride hydrate is a reversible competitive inhibitor of serine proteases, specifically targeting trypsin-like enzymes. It exhibits inhibitory constants (Kis) of 20 μM for Tryptase, 21 μM for Trypsin, 97 μM for uPA, 110 μM for Factor Xa, 320 μM for Thrombin, and 750 μM for tPA. This compound is widely utilized in biochemical research to study proteolytic processes and enzyme activity related to various physiological and pathological conditions.
  44. Trypsin Inhibitor

    Camostat is an orally active inhibitor of trypsin, functioning by modulating proteolytic activity in various biological systems. This compound has demonstrated the ability to reduce pancreatic fibrosis in experimental models, specifically by inhibiting the proliferation and activation of pancreatic stellate cells (PSCs). Camostat serves as a valuable tool in research investigating pancreatic diseases and fibrosis-related mechanisms.
  45. Matriptase Inhibitor

    Matriptase-IN-2 is a selective inhibitor of matriptase, a serine protease implicated in cartilage matrix degradation associated with osteoarthritis. With a Ki value of 5 nM, this secondary amide compound effectively inhibits matriptase activity, thereby preventing cartilage degradation. Matriptase-IN-2 is designed for research applications focused on understanding the role of matriptase in osteoarthritis pathology and potential therapeutic strategies.
  46. Plasminogen Activator

    Tenecteplase is a genetically modified tissue plasminogen activator, designed to enhance thrombolytic efficacy. By introducing mutations in three specific gene loci, Tenecteplase facilitates the conversion of plasminogen to plasmin, promoting fibrinolysis. This reagent is primarily employed in research applications related to acute ischemic stroke, enabling investigations into treatment strategies and mechanisms of thrombus resolution.
  47. Serine/Threonine Kinase Inhibitor

    Tilpisertib is a selective serine/threonine kinase inhibitor that targets key signaling pathways involved in cellular proliferation and survival. It has demonstrated significant antitumor activity, making it a valuable tool for cancer research and drug development. This compound is particularly useful for studying mechanisms of resistance in cancer therapies and evaluating the therapeutic potential of kinase inhibition in various tumor models.
  48. Serine Protease

    Recombinant Kex2 protease is a membrane-bound, calcium-dependent serine protease that selectively cleaves carboxyl-terminal peptide bonds at dibasic amino acids. This enzyme plays a critical role in protein processing and maturation within cells. It is widely utilized in biological research for studying proteolytic pathways and for applications involving protein engineering and purification strategies.
  49. proteinase K inhibitor

    MeOSuc-AAPF-CMK is a potent inhibitor of proteinase K, acting through the binding of its active site. This compound is primarily utilized in biochemical research to study protein degradation and enzyme inhibition mechanisms. Its effectiveness in blocking proteinase K activity makes it a valuable tool for investigating proteolytic pathways and cellular processes involving protein turnover.
  50. Hepsin Inhibitor

    Hepln-13 is a selective Hepsin inhibitor, demonstrating an IC50 of 0.33 μM. Its potency and oral bioavailability make it a valuable tool for investigating the role of Hepsin in metastatic prostate cancer. Researchers can employ Hepln-13 to explore therapeutic strategies targeting Hepsin-mediated pathways in cancer progression.

Items 1-50 of 149

Page
per page
Set Descending Direction